G1 Therapeutics, Inc.
GTHX · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Market Cap | $129,614 | $237,381 | $158,108 | $74,560 |
| - Cash | $15,137 | $19,950 | $32,281 | $94,352 |
| + Debt | $47,964 | $47,089 | $57,173 | $4,676 |
| Enterprise Value | $162,441 | $264,520 | $183,000 | -$15,116 |
| Revenue | $16,546 | $14,476 | $14,873 | $12,300 |
| % Growth | 14.3% | -2.7% | 20.9% | – |
| Gross Profit | $15,813 | $13,397 | $13,617 | $9,224 |
| % Margin | 95.6% | 92.5% | 91.6% | 75% |
| EBITDA | -$2,622 | -$8,121 | -$7,728 | -$15,057 |
| % Margin | -15.8% | -56.1% | -52% | -122.4% |
| Net Income | -$5,469 | -$10,219 | -$10,878 | -$18,204 |
| % Margin | -33.1% | -70.6% | -73.1% | -148% |
| EPS Diluted | -0.1 | -0.2 | -0.21 | -0.35 |
| % Growth | 50% | 4.8% | 40% | – |
| Operating Cash Flow | -$5,274 | -$8,898 | -$12,792 | -$10,577 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$5,274 | -$8,898 | -$12,792 | -$10,577 |